Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897088 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
A Phase 3 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT03897088 is a Phase 3 study of Scalp Psoriasis that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 231 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT03897088, a Phase 3 study of Scalp Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
Conditions Studied
Interventions
- DRUG PART 1: Double-blind Placebo-controlled
- DRUG PART 2: Double-blind Active Treatment Extension
Study Locations (20)
California
- SPARC Site 18 - Encinitas
- SPARC Site 7 - Fountain Valley
- SPARC Site 3 - Fremont
- SPARC Site 12 - Huntington Beach
- SPARC Site 9 - Los Angeles
- SPARC Site 2 - Los Angeles
- SPARC Site 14 - Santa Monica
Florida
- SPARC Site 21 - Coral Gables
- SPARC Site 19 - Margate
- SPARC Site 5 - Sweetwater
Texas
- SPARC Site 17 - Cypress
- SPARC Site 11 - Houston
- SPARC Site 6 - Webster
New York
- SPARC Site 4 - Forest Hills
- SPARC Site 16 - New York
New Jersey
- SPARC Site 13 - East Windsor
Ohio
- SPARC Site 01 - Beachwood
Oregon
- SPARC Site 20 - Portland
Rhode Island
- SPARC Site 8 - Johnston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897088
The ClinicalTrials.gov registry entry for NCT03897088 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which PART 1: Double-blind Placebo-controlled is the first listed.
NCT03897088 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03897088 about?
NCT03897088 is a clinical study titled "Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis". This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
What is the current status of trial NCT03897088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 231 participants. The study started on 2019-03-29. Estimated completion is 2022-02-17.
What conditions does trial NCT03897088 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT03897088?
The interventions under investigation include: PART 1: Double-blind Placebo-controlled (DRUG), PART 2: Double-blind Active Treatment Extension (DRUG).
Who is sponsoring clinical trial NCT03897088?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897088 being conducted?
This trial has 20 study locations across California, Florida, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.